You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
国务院:新冠疫苗III期临床试验初步显示良好安全性
阿思达克 10-21 12:23
国家科技部社会发展科技司副司长田保国在国务院联防联控机制新闻发布会上表示,内地新冠疫苗研发工作总体上处於领先地位,每条技术路线都有进入临床研究阶段的疫苗。

目前,已经有13个疫苗进入临床试验。其中,灭活疫苗和腺病毒载体疫苗两种技术路线共4个疫苗进入了III期临床试验。

4个进入III期临床试验阶段的新冠疫苗,总体上进展顺利。截至目前共接种约6万名受试者,未收到严重不良反应的报告,初步显示良好的安全性。

预计年底新冠疫苗年产能可达6.1亿剂。国家药监局将依法依规,第一时间完成技术审评,保障安全有效、质量可控的疫苗尽快上市。(ta/u)

~

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account